|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.27 USD | -0.47% |
|
-2.88% | -11.34% |
| May. 10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
| May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
Exelixis, Inc. at its Annual Meeting of Shareholders of 2023, approved election to the Board of Directors of Farallon Capital Management, L.L.C. director candidate: Dave Johnson.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.34% | 6.2B | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -0.38% | 21.93B | |
| -12.15% | 22.34B | |
| -7.66% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
EXELIXIS, INC. 
